Abstract:Introduction Although a relationship between prostate cancer and serum total testosterone (TT) has been studied, previous evidences were contradictory. Although a relationship between prostate cancer and serum total testosterone (TT) in terms of cancer biology as well as sexual function has been studied, previous evidences were contradictory and not organized very well. Objective We investigated the changes in TT levels after robot-assisted radical prostatectomy (RARP) for prostate cancer as a prospective surveillance. Methods From July 2015 to January 2022, 290 patients out of 1,343 prostate biopsies performed in our hospital underwent RARP with a diagnosis of localized prostate cancer. TT measurements were performed at 6:00 early morning on admission to all patients for biopsy. Of these, we studied 76 patients whose TT values have been measured during postoperative follow-up. TT values were measured 1 month after RARP, every 3 months until 36 months thereafter, and every 6 to 12 months thereafter for up to 72 months postoperatively. Results The median and quartile of age, serum PSA and TT (pre-TT) values at biopsy of the 76 patients were 69 years (64–72 years), 7.47 ng/mL (5.65–12.74 ng/mL) and 4.03 ng/mL (2.96–4.83 ng/mL), respectively. There was no significant correlation between age and pre-TT values (p = 0.21). RARP was performed an average of 2.9 months after biopsy. The median follow-up period was 43 months (31–60 months). PSA recurrence was observed in 18 patients (23.7%), with 3- and 5-year PSA non-recurrence rates of 77.4% and 74.9%, respectively. There was no significant difference in pre-TT values between patients with or without PSA recurrence (p = 0.107). Analysis of TT values at each observation period after RARP showed relative increase by an average of 23.4% (after 1 month) to 41.6% (after 36 months) when compared with pre-TT values. Further analysis of dividing 76 patients into 2 groups by a pre-TT value of 3.00 ng/mL showed that only in the low pre-TT group (pre-TT < 3.00 ng/mL: 21 cases, 27.6%), the rate of increase in TT values over pre-TT was significantly higher than that in the normal pre-TT group (pre-TT ≥ 3.00 ng/mL: 55 cases, 72.4%) at each observation period up to 72 months after RARP except 33 and 54 months Conclusions The transition of postoperative TT values in the patients who underwent RARP continued to show a significant increase at each observation period only in the group with low TT values preoperatively, suggesting that biochemical hypogonadism may have been presumably caused by prostate cancer-bearing conditions preoperatively in these patients with low TT values. Disclosure No.

(166) Serum Testosterone Level As A Predictor Of Biochemical Recurrence In Men With Prostate Cancer

(108) Serum Testosterone Level As A Predictor Of Biochemical Recurrence In Men With Prostate Cancer

(076) Serum Testosterone Level As A Predictor Of Adverse Pathological Outcomes In Men With Prostate Cancer

Management of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer

(062) The Risk Of Biochemical Recurrence Of Prostate Cancer In Men Receiving Testosterone Replacement Therapy Following Radical Prostatectomy

(123) Postoperative Changes of Serum Total Testosterone Levels in Patients with Prostate Cancer After Robot-Assisted Radical Prostatectomy

(109) Contemporary High-Level Radiation Therapy Prostate Cancer Trials May Underestimate The Risk Of Biochemical Recurrence

Testosterone Therapy in Men After Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer

(085) Long-Term Outcomes of Testosterone Replacement Therapy Delaying Biochemical Recurrence Post-RARP: Frequency-Matched Case-Control Study

Is there a relationship between testosterone and androgen receptor with prostatectomy outcomes?

The Association between Patient Characteristics and Biochemical Recurrence after Radical Prostatectomy

Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer

Low Serum Testosterone Predicts Upgrading and Upstaging of Prostate Cancer after Radical Prostatectomy

Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free Interval

(087) Testosterone Replacement Therapy in Men on Active Surveillance for Prostate Cancer: Using a Novel Database to Examine Disease Progression

The relationship between serum testosterone and progression of advanced prostate cancer

(271) Characterizing Testosterone Profiles In Men With Testis Cancer Prior To Radical Orchiectomy

The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy

(107) Identifying Predictors Of Low Testosterone Levels In Men With Testicular Cancer After Radical Orchiectomy

Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy

Risk Factors for Biochemical Recurrence after Radical Prostatectomy: a Single Center Analysis